Introduction: To evaluate the effect of an intravitreal injection of bevacizumab at the time of rhegmatogenous retinal detachment (RRD) surgery, on postoperative proliferative vitreoretinopathy (PVR) in high-risk patients selected by laser flare photometry. Methods: This single-center observational retrospective cohort study included 137 consecutive patients who underwent pars plana vitrectomy and gas tamponade for primary RRD with increased aqueous flare between July 2016 and June 2021. From June 2019, an intravitreal injection of bevacizumab was administered as an adjunct to RRD repair. Patients who underwent surgery before this time and who did not receive intravitreal bevacizumab served as controls. The main outcome was the rate of retinal redetachment due to PVR. Results: The median flare value was 22.0 (16.5–36.5) pc/ms in the control group and 28.2 (19.7–41.0) pc/ms in the bevacizumab group (p = 0.063). Eyes treated with bevacizumab were more likely to have macula-off RRD (p = 0.003), grade B PVR (p = 0.038), and worse visual acuity (p = 0.004) than controls. The rate of PVR redetachment was significantly lower in the bevacizumab group (11.1%) than in the control (30.1%) (p = 0.012). This difference was more pronounced after adjusting for potential confounding factors (p = 0.005); the risk of developing PVR was 4.5-fold higher in controls (95% CI, 1.6–12.8). After adjustment, the final median visual acuity was also significantly higher in eyes treated with bevacizumab (p = 0.025). Conclusion: This pilot study provides preliminary evidence that bevacizumab may reduce the risk of PVR-related recurrent RRD and improve visual outcomes in high-risk patients selected by laser flare photometry.

1.
Rowe
JA
,
Erie
JC
,
Baratz
KH
,
Hodge
DO
,
Gray
DT
,
Butterfield
L
.
Retinal detachment in olmsted county, Minnesota, 1976 through 1995
.
Ophthalmology
.
1999 Jan
106
1
154
9
.
2.
Charteris
DG
.
Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment
.
Br J Ophthalmol
.
1995 Oct
79
10
953
60
.
3.
Pastor
JC
,
Rojas
J
,
Pastor-Idoate
S
,
Di Lauro
S
,
Gonzalez-Buendia
L
,
Delgado-Tirado
S
.
Proliferative vitreoretinopathy: a new concept of disease pathogenesis and practical consequences
.
Prog Retin Eye Res
.
2016 Mar
51
125
55
.
4.
Chen
C
,
Chen
P
,
Liu
X
,
Li
H
.
Combined 5-fluorouracil and low molecular weight heparin for the prevention of postoperative proliferative vitreoretinopathy in patients with retinal detachment: a meta-analysis
.
Front Med
.
2021
;
8
:
790460
.
5.
Banerjee
PJ
,
Quartilho
A
,
Bunce
C
,
Xing
W
,
Zvobgo
TM
,
Harris
N
.
Slow-release dexamethasone in proliferative vitreoretinopathy: a prospective, randomized controlled clinical trial
.
Ophthalmology
.
2017 Jun
124
6
757
67
.
6.
Falavarjani
KG
,
Hadavandkhani
A
,
Parvaresh
MM
,
Modarres
M
,
Naseripour
M
,
Alemzadeh
SA
.
Intra-silicone oil injection of methotrexate in retinal reattachment surgery for proliferative vitreoretinopathy
.
Ocul Immunol Inflamm
.
2020 Apr
28
3
513
6
.
7.
Ahmadieh
H
,
Nourinia
R
,
Ragati Haghi
A
,
Ramezani
A
,
Entezari
M
,
Rahmani
G
.
Oral colchicine for prevention of proliferative vitreoretinopathy: a randomized clinical trial
.
Acta Ophthalmol
.
2015 Mar
93
2
e171
2
.
8.
Armstrong
D
,
Augustin
AJ
,
Spengler
R
,
Al-Jada
A
,
Nickola
T
,
Grus
F
.
Detection of vascular endothelial growth factor and tumor necrosis factor alpha in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker
.
Ophthalmologica
.
1998
;
212
(
6
):
410
4
.
9.
Ricker
LJAG
,
Kijlstra
A
,
Kessels
AGH
,
de Jager
W
,
Liem
ATA
,
Hendrikse
F
.
Interleukin and growth factor levels in subretinal fluid in rhegmatogenous retinal detachment: a case-control study
.
PLoS One
.
2011 Apr
6
4
e19141
.
10.
Ricker
LJAG
,
Dieudonné
SC
,
Kessels
AGH
,
Rennel
ES
,
Berendschot
TTJM
,
Hendrikse
F
.
Antiangiogenic isoforms of vascular endothelial growth factor predominate in subretinal fluid of patients with rhegmatogenous retinal detachment and proliferative vitreoretinopathy
.
Retina
.
2012 Jan
32
1
54
9
.
11.
Citirik
M
,
Kabatas
EU
,
Batman
C
,
Akin
KO
,
Kabatas
N
.
Vitreous vascular endothelial growth factor concentrations in proliferative diabetic retinopathy versus proliferative vitreoretinopathy
.
Ophthalmic Res
.
2012
;
47
(
1
):
7
12
.
12.
Ichsan
AM
,
Windy
DA
,
Muhiddin
HS
,
Budu
,
Massi
MN
,
Islam
IC
.
Comparison between vascular endothelial growth factor and platelet-derived growth factor levels in rhegmatogenous retinal detachment
.
J Ophthalmol
.
2021 Dec
2021
2688837
.
13.
Pennock
S
,
Kim
D
,
Mukai
S
,
Kuhnle
M
,
Chun
DW
,
Matsubara
J
.
Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease
.
Am J Pathol
.
2013 May
182
5
1659
70
.
14.
Pennock
S
,
Haddock
LJ
,
Eliott
D
,
Mukai
S
,
Kazlauskas
A
.
Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy
.
Prog Retin Eye Res
.
2014 May
40
16
34
.
15.
Ghasemi Falavarjani
K
,
Hashemi
M
,
Modarres
M
,
Hadavand Khani
A
.
Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy
.
Eye
.
2014 May
28
5
576
80
.
16.
Hsu
J
,
Khan
MA
,
Shieh
W-S
,
Chiang
A
,
Maguire
JI
,
Park
CH
.
Effect of serial intrasilicone oil bevacizumab injections in eyes with recurrent proliferative vitreoretinopathy retinal detachment
.
Am J Ophthalmol
.
2016 Jan
161
65
70.e1-2
.
17.
Zhao
X-Y
,
Xia
S
,
Wang
E-Q
,
Chen
Y-X
.
Efficacy of intravitreal injection of bevacizumab in vitrectomy for patients with proliferative vitreoretinopathy retinal detachment : a meta-analysis of prospective studies
.
Retina
.
2018 Mar
38
3
462
70
.
18.
Kon
CH
,
Asaria
RH
,
Occleston
NL
,
Khaw
PT
,
Aylward
GW
.
Risk factors for proliferative vitreoretinopathy after primary vitrectomy: a prospective study
.
Br J Ophthalmol
.
2000 May
84
5
506
11
.
19.
Asaria
RHY
,
Kon
CH
,
Bunce
C
,
Charteris
DG
,
Wong
D
,
Luthert
PJ
.
How to predict proliferative vitreoretinopathy
.
Ophthalmology
.
2001 Jul
108
7
1184
6
.
20.
Sala-Puigdollers
A
,
Fernández
I
,
Coco
RM
,
Sanabria
MR
,
Rodríguez de la Rúa
E
,
Ruiz-Moreno
JM
.
External validation of existing formulas to predict the risk of developing proliferative vitreoretinopathy: the retina 1 project; report 5
.
Retina
.
2013 Sep
33
8
1519
27
.
21.
Schröder
S
,
Muether
PS
,
Caramoy
A
,
Hahn
M
,
Abdel-Salam
M
,
Diestelhorst
M
.
Anterior chamber aqueous flare is a strong predictor for proliferative vitreoretinopathy in patients with rhegmatogenous retinal detachment
.
Retina
.
2012 Jan
32
1
38
42
.
22.
Hoerster
R
,
Hermann
MM
,
Rosentreter
A
,
Muether
PS
,
Kirchhof
B
,
Fauser
S
.
Profibrotic cytokines in aqueous humour correlate with aqueous flare in patients with rhegmatogenous retinal detachment
.
Br J Ophthalmol
.
2013 Apr
97
4
450
3
.
23.
Conart
J-B
,
Kurun
S
,
Ameloot
F
,
Tréchot
F
,
Leroy
B
,
Berrod
J-P
.
Validity of aqueous flare measurement in predicting proliferative vitreoretinopathy in patients with rhegmatogenous retinal detachment
.
Acta Ophthalmol
.
2017 Jun
95
4
e278
83
.
24.
Küchle
M
,
Nguyen
NX
,
Hannappel
E
,
Beck
W
,
Ho
ST
,
Naumann
GO
.
Tyndallometry with the laser flare cell meter and biochemical protein determination in the aqueous humor of eyes with pseudoexfoliation syndrome
.
Ophthalmologe
.
1994 Oct
91
5
578
84
.
25.
Machemer
R
,
Aaberg
TM
,
Freeman
HM
,
Irvine
AR
,
Lean
JS
,
Michels
RM
.
An updated classification of retinal detachment with proliferative vitreoretinopathy
.
Am J Ophthalmol
.
1991 Aug
112
2
159
65
.
26.
Herbort
CP
,
Tugal-Tutkun
I
,
Neri
P
,
Pavésio
C
,
Onal
S
,
LeHoang
P
.
Failure to integrate quantitative measurement methods of ocular inflammation hampers clinical practice and trials on new therapies for posterior uveitis
.
J Ocul Pharmacol Ther
.
2017 May
33
4
263
77
.
27.
Tousi
A
,
Hasanpour
H
,
Soheilian
M
.
Intravitreal injection of bevacizumab in primary vitrectomy to decrease the rate of retinal redetachment: a randomized pilot study
.
J Ophthalmic Vis Res
.
2016 Sep
11
3
271
6
.
28.
Girard
P
,
Mimoun
G
,
Karpouzas
I
,
Montefiore
G
.
Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery
.
Retina
.
1994
;
14
(
5
):
417
24
.
29.
Yoshino
Y
,
Ideta
H
,
Nagasaki
H
,
Uemura
A
.
Comparative study of clinical factors predisposing patients to proliferative vitreoretinopathy
.
Retina
.
1989
;
9
(
2
):
97
100
.
30.
Tseng
W
,
Cortez
RT
,
Ramirez
G
,
Stinnett
S
,
Jaffe
GJ
.
Prevalence and risk factors for proliferative vitreoretinopathy in eyes with rhegmatogenous retinal detachment but no previous vitreoretinal surgery
.
Am J Ophthalmol
.
2004 Jun
137
6
1105
15
.
31.
Bonnet
M
.
Clinical risk factors of vitreoretinal proliferations in rhegmatogenous retinal detachment
.
J Fr Ophtalmol
.
1994
17
8–9
530
40
.
32.
Pastor
JC
.
Proliferative vitreoretinopathy: an overview
.
Surv Ophthalmol
.
1998 Aug
43
1
3
18
.
33.
Pastor
JC
,
de la Rúa
ER
,
Martín
F
.
Proliferative vitreoretinopathy: risk factors and pathobiology
.
Prog Retin Eye Res
.
2002 Jan
21
1
127
44
.
34.
London
NJS
,
Kaiser
RS
,
Khan
MA
,
Alshareef
RA
,
Khuthaila
M
,
Shahlaee
A
.
Determining the effect of low-dose isotretinoin on proliferative vitreoretinopathy: the DELIVER trial
.
Br J Ophthalmol
.
2019 Sep
103
9
1306
13
.
35.
Mitry
D
,
Awan
MA
,
Borooah
S
,
Siddiqui
MAR
,
Brogan
K
,
Fleck
BW
.
Surgical outcome and risk stratification for primary retinal detachment repair: results from the Scottish Retinal Detachment study
.
Br J Ophthalmol
.
2012 May
96
5
730
4
.
36.
Lei
H
,
Rheaume
M-A
,
Kazlauskas
A
.
Recent developments in our understanding of how Platelet-Derived Growth Factor (PDGF) and its receptors contribute to proliferative vitreoretinopathy
.
Exp Eye Res
.
2010 Mar
90
3
376
81
.
37.
Lei
H
,
Velez
G
,
Hovland
P
,
Hirose
T
,
Gilbertson
D
,
Kazlauskas
A
.
Growth Factors outside the PDGF family drive experimental PVR
.
Invest Ophthalmol Vis Sci
.
2009 Jul
50
7
3394
403
.
38.
Pennock
S
,
Kazlauskas
A
.
Vascular endothelial growth factor A competitively inhibits Platelet-Derived Growth Factor (PDGF)-dependent activation of PDGF receptor and subsequent signaling events and cellular responses
.
Mol Cell Biol
.
2012 May
32
10
1955
66
.
39.
Zhu
Q
,
Ziemssen
F
,
Henke-Fahle
S
,
Tatar
O
,
Szurman
P
,
Aisenbrey
S
.
Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization
.
Ophthalmology
.
2008 Oct
115
10
1750
5
. e1.
40.
Mietz
H
,
Heimann
K
.
Onset and recurrence of proliferative vitreoretinopathy in various vitreoretinal disease
.
Br J Ophthalmol
.
1995 Oct
79
10
874
7
.
You do not currently have access to this content.